185 related articles for article (PubMed ID: 34183658)
1. Restoration of the molecular clock is tumor suppressive in neuroblastoma.
Moreno-Smith M; Milazzo G; Tao L; Fekry B; Zhu B; Mohammad MA; Di Giacomo S; Borkar R; Reddy KRK; Capasso M; Vasudevan SA; Sumazin P; Hicks J; Putluri N; Perini G; Eckel-Mahan K; Burris TP; Barbieri E
Nat Commun; 2021 Jun; 12(1):4006. PubMed ID: 34183658
[TBL] [Abstract][Full Text] [Related]
2. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
3. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
4. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
5. Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.
Lee AC; Shih YY; Zhou F; Chao TC; Lee H; Liao YF; Hsu WM; Hong JH
J Mol Med (Berl); 2019 Mar; 97(3):325-339. PubMed ID: 30612140
[TBL] [Abstract][Full Text] [Related]
6. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
7.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
8. TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.
Zhang X; Zhan S; Guan X; Zhang Y; Lu J; Yu Y; Jin Y; Yang Y; Chu P; Hong E; Yang H; Ren H; Geng D; Wang Y; Zhou P; Guo Y; Chang Y
Cancer Sci; 2023 Jul; 114(7):2860-2870. PubMed ID: 37094904
[TBL] [Abstract][Full Text] [Related]
9. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
10. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
[TBL] [Abstract][Full Text] [Related]
11. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
[TBL] [Abstract][Full Text] [Related]
12. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
13. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.
Boboila S; Lopez G; Yu J; Banerjee D; Kadenhe-Chiweshe A; Connolly EP; Kandel JJ; Rajbhandari P; Silva JM; Califano A; Yamashiro DJ
Oncogene; 2018 Oct; 37(40):5451-5465. PubMed ID: 29880876
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.
Taylor JS; Zeki J; Ornell K; Coburn J; Shimada H; Ikegaki N; Chiu B
J Pediatr Surg; 2019 Jun; 54(6):1192-1197. PubMed ID: 30879743
[TBL] [Abstract][Full Text] [Related]
16. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.
Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G
Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037
[TBL] [Abstract][Full Text] [Related]
17. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
18. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
19. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
[TBL] [Abstract][Full Text] [Related]
20. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
